☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
diffuse large B-cell lymphoma
Antengene's Receives NMPA's IND Approval for P-Ib MATCH Study of ATG-008 (onatasertib) ATG-010 (selinexor) to Treat Diffuse Large...
November 2, 2021
Genentech Reports Results of Polivy (polatuzumab vedotin-piiq) + R-CHP in P-III POLARIX Trial for the Treatment of Diffuse Large B...
August 9, 2021
Celltrion Presents Real-World Data of Truxima (biosimilar- rituximab) for Diffuse Large B-Cell Lymphoma at EHA 2021
June 14, 2021
Incyte and MorphoSys Report First Patient Dosing in P-III frontMIND Study of Tafasitamab + Lenalidomide as a 1L Treatment for DLBC...
May 12, 2021
ADC Therapeutics' Zynlonta (loncastuximab tesirine-lpyl) Receives the US FDA's Approval for the Treatment of R/R Diffuse Large B-C...
April 23, 2021
Chugai's Polivy Receives MHLW's Approval for Relapsed or Refractory Diffuse Large B-cell Lymphoma
March 25, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.